Toll样受体在神经系统相关疾病中的研究进展
Research Progress of Toll-Like Receptors in Neurosystem-Related Diseases
DOI: 10.12677/acm.2024.1492513, PDF,   
作者: 梁欣怡, 张宏阁, 李 豆, 姚佳乐, 杨梓钰：延安大学咸阳医院神经内科，陕西 咸阳；延安大学医学院，陕西 延安；张 维*：延安大学咸阳医院神经内科，陕西 咸阳；眉山心脑血管病医院神经内科，四川 眉山
关键词: Toll样受体；神经系统疾病；炎症；Toll-Like Receptors； Nervous System Disease； Inflammatory
摘要: Toll样受体(TLRs)是一种I型跨膜蛋白，作为一种模式识别受体，可以诱导天然免疫。近年来，TLRs在神经系统相关疾病中的作用受到了人们广泛的关注，大量的研究表明，TLRs介导的神经炎症反应在脑血管疾病、神经退行性疾病以及中枢脱髓鞘疾病中有着重要的作用。故本文就其在几种较为典型的神经系统疾病中的研究进展做一综述，以期为相关领域研究提供参考。
Abstract: Toll-like receptors (TLRs) are a type I transmembrane protein that acts as a pattern recognition receptor and can induce innate immunity. In recent years, the role of TLRs in nervous system-related diseases has received extensive attention. A large number of studies have shown that TLRs mediated neuroinflammatory response plays an important role in cerebrovascular diseases, neurodegenerative diseases and central demyelinating diseases. Therefore, this article reviews the research progress in several typical nervous system diseases in order to provide reference for the research in related fields.
文章引用：梁欣怡, 张维, 张宏阁, 李豆, 姚佳乐, 杨梓钰. Toll样受体在神经系统相关疾病中的研究进展[J]. 临床医学进展, 2024, 14(9): 667-673. https://doi.org/10.12677/acm.2024.1492513

参考文献

[1] Wang, Y., Ge, P. and Zhu, Y. (2013) TLR2 and TLR4 in the Brain Injury Caused by Cerebral Ischemia and Reperfusion. Mediators of Inflammation, 2013, Article 124614. [Google Scholar] [CrossRef] [PubMed]
[2] Kumar, V. (2019) Toll-Like Receptors in the Pathogenesis of Neuroinflammation. Journal of Neuroimmunology, 332, 16-30. [Google Scholar] [CrossRef] [PubMed]
[3] Heidari, A., Yazdanpanah, N. and Rezaei, N. (2022) The Role of Toll-Like Receptors and Neuroinflammation in Parkinson’s Disease. Journal of Neuroinflammation, 19, Article No. 135. [Google Scholar] [CrossRef] [PubMed]
[4] Deng, S., Chen, X., Lei, Q. and Lu, W. (2022) AQP2 Promotes Astrocyte Activation by Modulating the TLR4/NfκB-p65 Pathway Following Intracerebral Hemorrhage. Frontiers in Immunology, 13, Article 847360. [Google Scholar] [CrossRef] [PubMed]
[5] Adhikarla, S.V., Jha, N.K., Goswami, V.K., Sharma, A., Bhardwaj, A., Dey, A., et al. (2021) TLR-Mediated Signal Transduction and Neurodegenerative Disorders. Brain Sciences, 11, Article 1373. [Google Scholar] [CrossRef] [PubMed]
[6] Anderson, K.V., Bokla, L. and Nüsslein-Volhard, C. (1985) Establishment of Dorsal-Ventral Polarity in the Drosophila Embryo: The Induction of Polarity by the Toll Gene Product. Cell, 42, 791-798. [Google Scholar] [CrossRef] [PubMed]
[7] Medzhitov, R., Preston-Hurlburt, P. and Janeway, C.A. (1997) A Human Homologue of the Drosophila Toll Protein Signals Activation of Adaptive Immunity. Nature, 388, 394-397. [Google Scholar] [CrossRef] [PubMed]
[8] Fitzgerald, K.A. and Kagan, J.C. (2020) Toll-Like Receptors and the Control of Immunity. Cell, 180, 1044-1066. [Google Scholar] [CrossRef] [PubMed]
[9] Kawai, T. and Akira, S. (2010) The Role of Pattern-Recognition Receptors in Innate Immunity: Update on Toll-Like Receptors. Nature Immunology, 11, 373-384. [Google Scholar] [CrossRef] [PubMed]
[10] 中华医学会, 中华医学会杂志社, 中华医学会全科医学分会, 等. 缺血性卒中基层诊疗指南(2021年) [J]. 中华全科医师杂志, 2021, 20(9): 927-946.
[11] Feigin, V.L., Stark, B.A., Johnson, C.O., Roth, G.A., Bisignano, C., Abady, G.G., et al. (2021) Global, Regional, and National Burden of Stroke and Its Risk Factors, 1990-2019: A Systematic Analysis for the Global Burden of Disease Study 2019. The Lancet Neurology, 20, 795-820. [Google Scholar] [CrossRef] [PubMed]
[12] Feigin, V.L., Owolabi, M.O., Feigin, V.L., Abd-Allah, F., Akinyemi, R.O., Bhattacharjee, N.V., et al. (2023) Pragmatic Solutions to Reduce the Global Burden of Stroke: A World Stroke Organization-Lancet Neurology Commission. The Lancet Neurology, 22, 1160-1206. [Google Scholar] [CrossRef] [PubMed]
[13] 中华医学会神经病学分会, 中华医学会神经病学分会脑血管病学组. 中国急性缺血性卒中诊治指南2023 [J]. 中华神经科杂志, 2024, 57(6): 523-559.
[14] Pascual, M., Calvo‐Rodriguez, M., Núñez, L., Villalobos, C., Ureña, J. and Guerri, C. (2021) Toll‐Like Receptors in Neuroinflammation, Neurodegeneration, and Alcohol‐Induced Brain Damage. IUBMB Life, 73, 900-915. [Google Scholar] [CrossRef] [PubMed]
[15] Amini, H., Knepp, B., Rodriguez, F., Jickling, G.C., Hull, H., Carmona-Mora, P., et al. (2023) Early Peripheral Blood Gene Expression Associated with Good and Poor 90-Day Ischemic Stroke Outcomes. Journal of Neuroinflammation, 20, Article No. 13. [Google Scholar] [CrossRef] [PubMed]
[16] Jiang, H., Sun, Z., Zhu, X., Li, F. and Chen, Q. (2023) Essential Genes Ptgs2, Tlr4, and Ccr2 Regulate Neuro-Inflammation during the Acute Phase of Cerebral Ischemic in Mice. Scientific Reports, 13, Article No. 13021. [Google Scholar] [CrossRef] [PubMed]
[17] Yao, X., Liu, S., Ding, W., Yue, P., Jiang, Q., Zhao, M., et al. (2017) TLR4 Signal Ablation Attenuated Neurological Deficits by Regulating Microglial M1/M2 Phenotype after Traumatic Brain Injury in Mice. Journal of Neuroimmunology, 310, 38-45. [Google Scholar] [CrossRef] [PubMed]
[18] 黄红丽, 陈建, 王化强, 等. 急性脑梗死患者血浆高迁移率族蛋白B1/Toll样受体4变化及其与脑梗死体积、神经功能缺损及预后的关系[J]. 国际神经病学神经外科学杂志, 2022, 49(2): 15-19.
[19] Fernández, G., Moraga, A., Cuartero, M.I., García-Culebras, A., Peña-Martínez, C., Pradillo, J.M., et al. (2018) TLR4-Binding DNA Aptamers Show a Protective Effect against Acute Stroke in Animal Models. Molecular Therapy, 26, 2047-2059. [Google Scholar] [CrossRef] [PubMed]
[20] Hernández-Jiménez, M., Abad-Santos, F., Cotgreave, I., Gallego, J., Jilma, B., Flores, A., et al. (2023) Safety and Efficacy of ApTOLL in Patients with Ischemic Stroke Undergoing Endovascular Treatment. JAMA Neurology, 80, 779-788. [Google Scholar] [CrossRef] [PubMed]
[21] Sansing, L.H., Harris, T.H., Welsh, F.A., Kasner, S.E., Hunter, C.A. and Kariko, K. (2011) Toll‐Like Receptor 4 Contributes to Poor Outcome after Intracerebral Hemorrhage. Annals of Neurology, 70, 646-656. [Google Scholar] [CrossRef] [PubMed]
[22] Fei, X., He, Y., Chen, J., Man, W., Chen, C., Sun, K., et al. (2019) The Role of Toll-Like Receptor 4 in Apoptosis of Brain Tissue after Induction of Intracerebral Hemorrhage. Journal of Neuroinflammation, 16, Article No. 234. [Google Scholar] [CrossRef] [PubMed]
[23] Longa, E.Z., Weinstein, P.R., Carlson, S. and Cummins, R. (1989) Reversible Middle Cerebral Artery Occlusion without Craniectomy in Rats. Stroke, 20, 84-91. [Google Scholar] [CrossRef] [PubMed]
[24] Mitsui, K., Ikedo, T., Kamio, Y., Furukawa, H., Lawton, M.T. and Hashimoto, T. (2020) TLR4 (Toll-Like Receptor 4) Mediates the Development of Intracranial Aneurysm Rupture. Hypertension, 75, 468-476. [Google Scholar] [CrossRef] [PubMed]
[25] Okada, T., Kawakita, F., Nishikawa, H., Nakano, F., Liu, L. and Suzuki, H. (2018) Selective Toll-Like Receptor 4 Antagonists Prevent Acute Blood-Brain Barrier Disruption after Subarachnoid Hemorrhage in Mice. Molecular Neurobiology, 56, 976-985. [Google Scholar] [CrossRef] [PubMed]
[26] Ma, C., Zhou, W., Yan, Z., Qu, M. and Bu, X. (2015) Toll-Like Receptor 4 (TLR4) Is Correlated with Delayed Cerebral Ischemia (DCI) and Poor Prognosis in Aneurysmal Subarachnoid Hemorrhage. Journal of the Neurological Sciences, 359, 67-71. [Google Scholar] [CrossRef] [PubMed]
[27] 中华医学会神经病学分会帕金森病及运动障碍学组, 中国医师协会神经内科医师分会帕金森病及运动障碍学组. 中国帕金森病治疗指南(第四版) [J]. 中华神经科杂志, 2020, 53(12): 973-986.
[28] Zeng, X., Geng, W., Jia, J., Chen, L. and Zhang, P. (2018) Cellular and Molecular Basis of Neurodegeneration in Parkinson Disease. Frontiers in Aging Neuroscience, 10, Article 109. [Google Scholar] [CrossRef] [PubMed]
[29] Tolosa, E., Garrido, A., Scholz, S.W. and Poewe, W. (2021) Challenges in the Diagnosis of Parkinson’s Disease. The Lancet Neurology, 20, 385-397. [Google Scholar] [CrossRef] [PubMed]
[30] Zheng, Z., Zhu, Z., Zhou, C., Cao, L. and Zhao, G. (2022) Burden of Parkinson Disease in China, 1990-2019: Findings from the 2019 Global Burden of Disease Study. Neuroepidemiology, 57, 51-64. [Google Scholar] [CrossRef] [PubMed]
[31] Kouli, A., Horne, C.B. and Williams-Gray, C.H. (2019) Toll-Like Receptors and Their Therapeutic Potential in Parkinson’s Disease and α-Synucleinopathies. Brain, Behavior, and Immunity, 81, 41-51. [Google Scholar] [CrossRef] [PubMed]
[32] Kin, K., Yasuhara, T., Kameda, M. and Date, I. (2019) Animal Models for Parkinson’s Disease Research: Trends in the 2000s. International Journal of Molecular Sciences, 20, Article 5402. [Google Scholar] [CrossRef] [PubMed]
[33] He, Y., Zhao, J., Dong, H., Zhang, X., Duan, Y., Ma, Y., et al. (2023) TLR2 Deficiency Is Beneficial at the Late Phase in MPTP-Induced Parkinson’ Disease Mice. Life Sciences, 333, Article 122171. [Google Scholar] [CrossRef] [PubMed]
[34] Zhang, Z., Liu, Z., Lv, A. and Fan, C. (2023) How Toll-Like Receptors Influence Parkinson’s Disease in the Microbiome-Gut-Brain Axis. Frontiers in Immunology, 14, Article 1154626. [Google Scholar] [CrossRef] [PubMed]
[35] Zhao, Z., Ning, J., Bao, X., Shang, M., Ma, J., Li, G., et al. (2021) Fecal Microbiota Transplantation Protects Rotenone-Induced Parkinson’s Disease Mice via Suppressing Inflammation Mediated by the Lipopolysaccharide-TLR4 Signaling Pathway through the Microbiota-Gut-Brain Axis. Microbiome, 9, Article No. 226. [Google Scholar] [CrossRef] [PubMed]
[36] 郭清华, 郭彦杰, 宋净洋, 等. 帕金森病患者血清中Toll样受体4及下游炎症因子的高表达与临床分期及分型的关系研究[J]. 国际神经病学神经外科学杂志, 2022, 49(3): 41-45.
[37] Dzamko, N., Gysbers, A., Perera, G., Bahar, A., Shankar, A., Gao, J., et al. (2016) Toll-Like Receptor 2 Is Increased in Neurons in Parkinson’s Disease Brain and May Contribute to Alpha-Synuclein Pathology. Acta Neuropathologica, 133, 303-319. [Google Scholar] [CrossRef] [PubMed]
[38] 中华医学会神经病学分会神经免疫学组. 多发性硬化诊断与治疗中国指南(2023版) [J]. 中华神经科杂志, 2024, 57(1): 10-23.
[39] Tian, D., Zhang, C., Yuan, M., Yang, X., Gu, H., Li, Z., et al. (2020) Incidence of Multiple Sclerosis in China: A Nationwide Hospital-Based Study. The Lancet Regional Health-Western Pacific, 1, Article 100010. [Google Scholar] [CrossRef] [PubMed]
[40] 赵培源, 陈少昀, 刘喜红, 等. 多发性硬化实验动物模型的研究与应用进展[J]. 中国实验动物学报, 2020, 28(3): 405-409.
[41] 韩晶晶, 张英, 姚瑞芹, 等. 敲除Toll样受体4基因对小鼠实验性自身免疫性脑脊髓炎的影响[J]. 神经解剖学杂志, 2022, 38(3): 287-292.
[42] Shao, W., Huang, Y., Wang, L., Li, P., Jia, Y. and Zhang, J. (2023) Expression of Fibrinogen-Like Protein 2 (Fgl2) on Toll-Like Receptor 9 (TLR9) Expression in Autoimmune Myelitis. International Immunopharmacology, 114, Article 109539. [Google Scholar] [CrossRef] [PubMed]
[43] Mustafa, A.M., Shaheen, A.M., Zaki, H.F. and Rabie, M.A. (2024) Nicorandil and Carvedilol Mitigates Motor Deficits in Experimental Autoimmune Encephalomyelitis-Induced Multiple Sclerosis: Role of TLR4/TRAF6/MAPK/NF-κB Signalling Cascade. International Immunopharmacology, 127, Article 111387. [Google Scholar] [CrossRef] [PubMed]
[44] Hossain, M.J., Morandi, E., Tanasescu, R., Frakich, N., Caldano, M., Onion, D., et al. (2018) The Soluble Form of Toll-Like Receptor 2 Is Elevated in Serum of Multiple Sclerosis Patients: A Novel Potential Disease Biomarker. Frontiers in Immunology, 9, Article 457. [Google Scholar] [CrossRef] [PubMed]

为你推荐